HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guerlain spa boutique opens at Waldorf-Astoria

This article was originally published in The Rose Sheet

Executive Summary

Luxury personal-care brand Guerlain has introduced the Guerlain Spa Boutique at the Waldorf-Astoria Hotel in New York, firm notes in a recent release. Boutique will offer the French brand's cosmetic, skin care and fragrance lines as well as booking services for the first Guerlain Spa, slated to open on the hotel's 19 floor in early 2008. Visitors to the spa will be able to indulge in signature Guerlain treatments, including the Exceptional Orchidée Impériale Treatment, among numerous beauty and wellness therapies. "We are thrilled to announce the collaboration between Guerlain and the Waldorf-Astoria Collection," Guerlain President and CEO Laurent Boillot says. "Guerlain is an icon in the premium cosmetic industry, with nearly 180 years of history and excellence in product development and service. Luxury, service, and the permanent search for excellence have been common traits for decades for both the Waldorf-Astoria and Guerlain.

You may also be interested in...



Biocon-Mylan's Plans For Broader US Fulphila Access, Glargine On Track

Biocon-Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.

JT Gains World-First Topical JAK Inhibitor Approval

Latest new drug approvals in Japan include the first anywhere for a topical JAK inhibitor and also a marketing clearance for a new contender in the large prostate cancer space.

QUOTED. 27 January 2020. John McKay.

Consultant John McKay encourages device makers to ask questions of the US FDA’s inspection team during a facility audit. Check out his advice here.

UsernamePublicRestriction

Register

RS015135

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel